免疫检查点抑制剂生物标志物:肿瘤取材部位的重要性与细胞病理学的挑战
本文综述免疫检查点抑制剂疗效预测生物标志物的现状,重点讨论PD-L1在肿瘤细胞或相关免疫细胞上的免疫组化检测,以及不同技术平台、抗体克隆、评分系统与适应证带来的复杂性。文章强调晚期癌症常以微创细胞学取材,细胞学标本应用这些标志物既有机遇也有风险。
要点
- PD-L1免疫组化检测是免疫检查点抑制剂疗效预测的主要生物标志物方向。
- 不同技术平台、抗体克隆与评分系统使诊断判读复杂化。
- 晚期癌症常以微创细胞学取材,细胞学标本应用PD-L1检测需关注其机遇与风险。
核心结论
- 免疫检查点抑制剂疗效难以预测,部分源于肿瘤免疫微环境的复杂性。
- 病理标本应用生物标志物预测治疗反应是病理医生在精准医学中的关键角色之一。
- 新兴生物标志物主要围绕肿瘤细胞或相关免疫细胞上PD-L1的免疫组化检测。
- 细胞学标本应用这些生物标志物至关重要,因当前药物适应证为晚期癌症,常经微创细胞学而非手术切除取材。
- 本综述总结免疫检查点抑制剂生物标志物现状,强调细胞学样本的机遇与威胁。
研究设计与样本
- 本文为综述,总结免疫检查点抑制剂生物标志物的当前状况,重点讨论细胞学样本的应用。
- 检索范围与文献纳入标准原文未报告。
主要发现
- 免疫检查点抑制剂在部分既往难治的晚期癌症中可见显著且持久的反应。
- 这些反应难以预测,使在合适时间对合适患者使用合适药物仍难以实现。
- 诊断领域已因不同技术平台、抗体克隆、评分系统及其使用适应证而变得复杂。
关键数值与推荐
- 生物标志物检测对象为肿瘤细胞或相关免疫细胞上的程序性细胞死亡配体1(PD-L1)。
临床怎么用
- 对晚期癌症常经微创细胞学取材的标本,应评估PD-L1等免疫检查点抑制剂生物标志物的检测可行性。
- 判读时需考虑技术平台、抗体克隆与评分系统的差异及其适应证。
局限性
- 肿瘤免疫微环境的复杂性及其在药效中的作用使反应预测困难。
- 不同技术平台、抗体克隆、评分系统与适应证造成诊断判读复杂。
- 细胞学样本应用这些生物标志物存在威胁与挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The recent emergence of immune checkpoint inhibitors for cancer therapy has created much excitement among cancer patients, drug and diagnostic developers, and health care professionals. This is due largely to the dramatic and sustained responses among some advanced cancers that were previously refractory to therapy. Unfortunately, these responses are difficult to predict, so the goal of the right drug for the right patient at the right time remains elusive. This is in part due to the complexity of the tumor immune microenvironment and its role in drug efficacy. The application of biomarkers to pathologic specimens to predict responses to therapy remains one of the key roles for pathologists in precision medicine. For the new immune checkpoint inhibitors, the emerging class of biomarkers revolves around the immunohistochemical detection of the drug target (or its ligand), programmed cell death ligand 1, on tumor cells or associated immune cells. The diagnostic terrain is already complex because of the involvement of different technology platforms, antibody clones, scoring systems, and indications for their use. The application of these biomarkers to cytologic specimens is critical because the current drug indications are for advanced-stage cancers that are often sampled by minimally invasive cytologic means rather than surgical resection. This review summarizes the current state of biomarkers for immune checkpoint inhibitors with an emphasis on the opportunities for and threats to cytologic samples. Cancer Cytopathol 2018;126:11-9. © 2017 American Cancer Society.
引用
- Clark DP. Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathology. Cancer Cytopathol. 2017. PMID: 29131530. doi:10.1002/cncy.21951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。